2023 World Conference on Lung Cancer (Posters)-P1.27. BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy

P1.27. BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy - PDF(Slides)

Back to course

Pdf Summary

A retrospective study analyzed the survival outcomes of patients with BRAF-mutated and BRAF-wt tumors in NADIM clinical trials. The study used samples from NADIM and NADIM II clinical trials, where locally advanced non-small cell lung cancer (NSCLC) patients were treated with neoadjuvant chemo-immunotherapy with Nivolumab. The presence of BRAF mutations in NSCLC patients treated with chemo-immunotherapy was analysed as a biomarker for patient prognosis.<br /><br />The study found that BRAF pathogenic variants may be a good prognostic factor in locally advanced NSCLC patients treated with neoadjuvant chemo-immunotherapy. The presence of BRAF variants could also be used as a biomarker. The study showed that 4.35% of patients had pathogenic/likely-pathogenic BRAF variants. Patients with BRAF mutations had a higher probability of being alive and with no evidence of progression compared to those without mutations. The results suggest that BRAF mutations may identify NSCLC patients who can benefit from neoadjuvant chemo-immunotherapy.<br /><br />The study also provided patient characteristics, including age, sex, smoking status, histology, and stage of the disease. The median follow-up for the patients was 35.1 months. The study was funded by liquidBiopsyLabPdH and contact information was provided for further inquiries.<br /><br />In summary, the study found that BRAF pathogenic variants may serve as a good prognostic factor in NSCLC patients treated with neoadjuvant chemo-immunotherapy. The presence of BRAF mutations could be used as a biomarker for patient prognosis. These findings suggest that BRAF mutations may help identify NSCLC patients who can benefit from this treatment approach.

Asset Subtitle

Lucia Robado de Lope

Meta Tag

Speaker Lucia Robado de Lope

Topic Early-Stage NSCLC: Innovation & New Technology

Keywords

retrospective study

survival outcomes

BRAF-mutated tumors

BRAF-wt tumors

NADIM clinical trials

NADIM II clinical trials

locally advanced non-small cell lung cancer

neoadjuvant chemo-immunotherapy

BRAF mutations

biomarker